Genelux price target lowered to $30 from $38 at Benchmark

Benchmark analyst Bruce Jackson lowered the firm’s price target on Genelux to $30 from $38 and keeps a Speculative Buy rating on the shares after the firm updated its model for Q3 results. The firm has raised the share count estimate to account for a possible capital raise in 2025, which drives the change in its price target.